Cited 2 times in

Respiratory syncytial virus prevention in children with congenital heart disease: who and how?

Title
Respiratory syncytial virus prevention in children with congenital heart disease: who and how?
Authors
Nam Kyun Kim;Jae Young Choi
Issue Date
2011
Journal Title
Korean Journal of Pediatrics
ISSN
1738-1061
Citation
Korean Journal of Pediatrics, Vol.54(5) : 197~200, 2011
Abstract
Respiratory syncytial virus (RSV) is a major cause of respiratory infection in children. Most of the pediatric population have RSV infection before the age of 2, and recurrent infections are common even within one season. Chronic lung disease, prematurity, along with congenital heart disease (CHD) are major risk factors in severe lower respiratory infection. In hemo-dynamically significant CHD patients with RSV infection, hospitalization is usually needed and the possibility of treatment in intensive care unit and the use of mechanical ventilator support are known to increase. Therefore the prevention of RSV infection in CHD patients is mandatory. The current standard for RSV prevention is immunoprophylaxis by palivizumab. Immunoprophylaxis is recommended monthly in hemodynamically significant CHD patients, up to 5 months. Motabizumab, a second generation drug and newly developing RSV vaccines are also expected to play a key role in RSV prevention in the future. The prophylaxis of RSV infection in CHD patients is cost-effective in both the medical aspect of the patients as well as the socio-economic aspect. Therefore an effort to promote prevention should be made by not only the family of the patients but also by the government
URI

http://ir.ymlib.yonsei.ac.kr/handle/22282913/94071
DOI
10.3345/kjp.2011.54.5.197
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Pediatrics
Yonsei Authors
사서에게 알리기
  feedback
Files in This Item:
T201103228.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse